Repligen (RGEN) Cash from Financing Activities (2010 - 2026)
Repligen (RGEN) posted quarterly Cash from Financing Activities of -$6.2 million for Q2 2026, up 38.8% year-over-year from -$4.5 million in Q2 2025, and down 11.85% quarter-over-quarter from -$5.5 million in Q1 2026.
Repligen (RGEN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Repligen (RGEN) has reported Cash from Financing Activities for 17 consecutive years, with -$6.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 38.8% year-over-year to -$6.2 million; the TTM figure through Jun 2026 stood at -$11.8 million (up 85.85% YoY), while the FY2025 annual figure was -$15.2 million, up 81.66% from the prior year.
- Cash from Financing Activities eased to -$6.2 million in Q2 2026 per RGEN's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $268.1 million in Q4 2023 and bottomed at -$69.6 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $7.0 million across 5 years, with a median of -$5.3 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 97956.57% — and 2024, when it slumped 8846.53%.
- Repligen's Cash from Financing Activities stood at -$274000.0 in 2022, then soared by 97956.57% to $268.1 million in 2023, then plunged by 99.46% to $1.4 million in 2024, then slumped by 86.54% to $195000.0 in 2025, then plunged by 3279.49% to -$6.2 million in 2026.
- Business Quant data shows RGEN's Cash from Financing Activities at -$6.2 million in Q2 2026, -$5.5 million in Q1 2026, and $195000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Repligen | 10.25 Bn | 9.24 Bn | 110.04 Mn | -6.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.20 Mn |
| Jun 30, 2026 | -6.20 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Jun 30, 2025 | -10.13 Mn |
| Jun 30, 2025 | -10.13 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | -69.60 Mn |
| Sep 30, 2024 | -69.60 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -8.97 Mn |
| Mar 31, 2024 | -8.97 Mn |